Phenobarbital Dosing in Newborns
For neonatal seizures, administer phenobarbital with a loading dose of 20 mg/kg IV over 10-15 minutes, followed by maintenance dosing of 3-4 mg/kg/day starting 24 hours after the loading dose. 1
Loading Dose
The FDA-approved loading dose for status epilepticus in pediatric patients is 15-20 mg/kg IV over 10-15 minutes 1. The 2023 ILAE guidelines on neonatal seizures support this dosing, with their reviewed evidence showing initial dosing of 20 mg/kg for phenobarbital in term neonates, with additional 20 mg/kg doses available for persistent seizures 2.
Key administration points:
- Administer intravenously over 10-15 minutes to avoid hypotension
- Do not exceed 60 mg/min infusion rate in any patient 1
- Therapeutic plasma levels (15-40 mcg/mL) are achieved within 2 hours of IV loading 3
- The higher end of the range (20 mg/kg) is preferred for rapid seizure control
Maintenance Dosing
Begin maintenance therapy 24 hours after the loading dose at 3-4 mg/kg/day 1, 4. This can be administered as a single daily injection given the long half-life (69-165 hours in neonates) 5.
Critical dosing considerations:
- Do not exceed 5 mg/kg/day to avoid drug accumulation 5
- Plasma levels remain stable for 48 hours after loading, requiring no immediate adjustment 5
- Monitor plasma phenobarbital levels at 24,48, and 72 hours after loading
Special Population: Very Low Birth Weight Infants
Exercise particular caution in preterm infants <1,500g, as they demonstrate higher plasma concentrations with standard dosing 6. A study of 24 very low birth weight infants showed that 70.8% exceeded therapeutic upper limits (40 mcg/mL) by 96 hours with standard dosing. There is a negative correlation between gestational age and phenobarbital levels, meaning younger gestational age infants achieve higher concentrations 6.
For these patients:
- Consider starting at the lower end of the loading dose range (15 mg/kg)
- Use maintenance doses of 3 mg/kg/day rather than 4 mg/kg/day
- Monitor plasma levels more frequently (every 24 hours for first 96 hours)
Efficacy Data
Phenobarbital demonstrates superior efficacy compared to alternatives. The ILAE task force found phenobarbital controlled seizures in 80% of neonates (24 of 30) versus only 28% for levetiracetam (15 of 53), with moderate quality evidence (RR = 0.35,95% CI = 0.22-0.56) 2. Phenobarbital showed equivalent efficacy to phenytoin as first-line therapy, but phenobarbital is preferred due to better safety profile and ease of administration.
Safety Monitoring
Monitor for hypotension, which occurs in approximately 17% of patients receiving phenobarbital 2. This is the most common adverse effect and typically occurs with rapid infusion.
Essential monitoring parameters:
- Blood pressure, respiration, and cardiac function during IV administration 1
- Plasma phenobarbital levels at 24,48,72, and 96 hours
- Clinical seizure activity and EEG if available
Duration of Therapy
Treatment duration depends on the underlying etiology and clinical response. For acute provoked seizures (HIE, stroke, hemorrhage), early discontinuation after 1-2 weeks is generally appropriate once the acute phase has resolved 5. Prolonged therapy beyond 2 weeks requires careful reassessment of risk-benefit ratio.
Etiology-Specific Considerations
For suspected channelopathies (e.g., KCNQ2/KCNQ3 variants suggested by positive family history), sodium channel blockers like phenytoin or carbamazepine should be used as first-line instead of phenobarbital, as 91% of ILAE task force respondents agreed on this approach 2.